Yee Marianne E M, Josephson Cassandra D, Winkler Anne M, Webb Jennifer, Luban Naomi L C, Leong Traci, Stowell Sean R, Fasano Ross M
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Division of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia.
Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
Transfusion. 2017 Nov;57(11):2738-2746. doi: 10.1111/trf.14282. Epub 2017 Aug 24.
Red blood cell (RBC) alloimmunization occurs at a high frequency in sickle cell anemia (SCA) despite serologic matching for Rh (C/c, E/e) and K antigens. RBC minor antigen genotyping allows for prediction of antigens and RH variants that may lead to alloimmunization.
RBC antigen genotyping was performed on chronically transfused pediatric SCA patients, using PreciseType human erythrocyte antigen (HEA), RHCE, and RHD BeadChip arrays. All patients received C/c, E/e, and K serologically matched units (Category 1); patients with prior RBC antibodies were also matched for Fy , Jk , and any antibodies (Category 2). The RBC genotypes of all leukoreduced (LR) units transfused over a 12-month period were determined by the prototype HEA-LR BeadChip assay.
There were 2320 RBC units transfused to 90 patients in 1135 transfusion episodes. Thirty-five (38.9%) patients had homozygous or compound heterozygous RH variants. Seven new alloantibodies were detected, with alloantibody incidence of 0.706 in 100 units for Category 2 transfusions and 0.068 in 100 units for Category 1 (p = 0.02). Three patients on Category 2 transfusions formed new anti-Js and had a higher rate of exposure to Js than those who did not form anti-Js (20.4 vs. 8.33 exposures/100 units, p = 0.02). The most frequent mismatches were S (43.9%), Do (43.9%), Fy (29.2%), M (28.4%), and Jk (28.1%).
Alloimmunization incidence was higher in those with prior RBC antibodies, suggesting that past immunologic responders are at higher risk for future alloimmunization and therefore may benefit from more extensive antigen matching beyond C/c, E/e, K, Fy , and Jk .
尽管在镰状细胞贫血(SCA)患者中进行了Rh(C/c、E/e)和K抗原的血清学匹配,但红细胞(RBC)同种免疫的发生率仍很高。RBC次要抗原基因分型有助于预测可能导致同种免疫的抗原和RH变异体。
使用PreciseType人类红细胞抗原(HEA)、RHCE和RHD BeadChip芯片对长期输血的小儿SCA患者进行RBC抗原基因分型。所有患者均接受C/c、E/e和K血清学匹配的血制品(1类);既往有RBC抗体的患者还进行了Fy、Jk及任何其他抗体的匹配(2类)。通过原型HEA-LR BeadChip检测法确定12个月内输注的所有白细胞滤除(LR)血制品的RBC基因型。
在1135次输血事件中,共向90例患者输注了2320单位RBC血制品。35例(38.9%)患者存在纯合或复合杂合RH变异体。检测到7种新的同种抗体,2类输血的同种抗体发生率为每100单位0.706,1类为每100单位0.068(p = 0.02)。3例接受2类输血的患者产生了新的抗-Js抗体,其接触Js的频率高于未产生抗-Js抗体的患者(20.4次暴露/100单位 vs. 8.33次暴露/100单位,p = 0.02)。最常见的不匹配抗原为S(43.9%)、Do(43.9%)、Fy(29.2%)、M(28.4%)和Jk(28.1%)。
既往有RBC抗体的患者同种免疫发生率更高,这表明既往有免疫反应的患者未来发生同种免疫的风险更高,因此可能受益于除C/c、E/e、K、Fy和Jk之外更广泛的抗原匹配。